398 related articles for article (PubMed ID: 23990460)
21. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
22. DNA Sequence Recognition of Human CXXC Domains and Their Structural Determinants.
Xu C; Liu K; Lei M; Yang A; Li Y; Hughes TR; Min J
Structure; 2018 Jan; 26(1):85-95.e3. PubMed ID: 29276034
[TBL] [Abstract][Full Text] [Related]
23. Cloning and characterization of the gene encoding the mouse homologue of CpG binding protein.
Carlone DL; Hart SR; Ladd PD; Skalnik DG
Gene; 2002 Jul; 295(1):71-7. PubMed ID: 12242013
[TBL] [Abstract][Full Text] [Related]
24. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of transcriptional regulation by methyl-CpG binding protein MBD1.
Fujita N; Shimotake N; Ohki I; Chiba T; Saya H; Shirakawa M; Nakao M
Mol Cell Biol; 2000 Jul; 20(14):5107-18. PubMed ID: 10866667
[TBL] [Abstract][Full Text] [Related]
26. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression.
Erfurth FE; Popovic R; Grembecka J; Cierpicki T; Theisler C; Xia ZB; Stuart T; Diaz MO; Bushweller JH; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2008 May; 105(21):7517-22. PubMed ID: 18483194
[TBL] [Abstract][Full Text] [Related]
27. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ
Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926
[TBL] [Abstract][Full Text] [Related]
28. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
[TBL] [Abstract][Full Text] [Related]
29. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
30. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
31. ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection.
Long HK; Blackledge NP; Klose RJ
Biochem Soc Trans; 2013 Jun; 41(3):727-40. PubMed ID: 23697932
[TBL] [Abstract][Full Text] [Related]
32. MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.
Skucha A; Ebner J; Schmöllerl J; Roth M; Eder T; César-Razquin A; Stukalov A; Vittori S; Muhar M; Lu B; Aichinger M; Jude J; Müller AC; Győrffy B; Vakoc CR; Valent P; Bennett KL; Zuber J; Superti-Furga G; Grebien F
Nat Commun; 2018 May; 9(1):1983. PubMed ID: 29777171
[TBL] [Abstract][Full Text] [Related]
33. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
[TBL] [Abstract][Full Text] [Related]
34. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain.
Cao F; Chen Y; Cierpicki T; Liu Y; Basrur V; Lei M; Dou Y
PLoS One; 2010 Nov; 5(11):e14102. PubMed ID: 21124902
[TBL] [Abstract][Full Text] [Related]
35. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
36. C1188D mutation abolishes specific recognition between MLL1-CXXC domain and CpG site by inducing conformational switch of flexible N-terminal.
Chen J; Qi Y; Duan Y; Duan M; Yang M
Proteins; 2020 Nov; 88(11):1401-1412. PubMed ID: 32519403
[TBL] [Abstract][Full Text] [Related]
37. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Kerry J; Godfrey L; Repapi E; Tapia M; Blackledge NP; Ma H; Ballabio E; O'Byrne S; Ponthan F; Heidenreich O; Roy A; Roberts I; Konopleva M; Klose RJ; Geng H; Milne TA
Cell Rep; 2017 Jan; 18(2):482-495. PubMed ID: 28076791
[TBL] [Abstract][Full Text] [Related]
38. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23).
Ono R; Taki T; Taketani T; Taniwaki M; Kobayashi H; Hayashi Y
Cancer Res; 2002 Jul; 62(14):4075-80. PubMed ID: 12124344
[TBL] [Abstract][Full Text] [Related]
39. Ets1 Plays a Critical Role in MLL/EB1-Mediated Leukemic Transformation in a Mouse Bone Marrow Transplantation Model.
Fu JF; Yen TH; Huang YJ; Shih LY
Neoplasia; 2019 May; 21(5):469-481. PubMed ID: 30974389
[TBL] [Abstract][Full Text] [Related]
40. MLL targets SET domain methyltransferase activity to Hox gene promoters.
Milne TA; Briggs SD; Brock HW; Martin ME; Gibbs D; Allis CD; Hess JL
Mol Cell; 2002 Nov; 10(5):1107-17. PubMed ID: 12453418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
